Ha Kung Wong

Ha Kung Wong

Ha Kung Wong practices general intellectual property (IP) law with an emphasis on complex patent and trade secret litigation, as well as IP transactions and contract negotiations for mergers, acquisitions, vendor agreements, and collaborations in pharmaceuticals, biologics, chemistry, medical devices, digital health, and artificial intelligence. Cases Ha Kung has litigated include those related to proton pump inhibitors, anti-epileptic drugs, anti-tussives, ADHD medications, injectable microspheres, RNAi products, antibiotics, and other pharmaceuticals. Ha Kung also has extensive experience with inter partes review, post-grant review, IP counseling, pre-suit investigations, licensing, and due diligence, including patent strength and freedom-to-operate analyses.


Representative Matters

  • Represented Alkermes against Luye Pharma on a patent related to injectable microsphere formulations for treatment of a variety of indications, including schizophrenia
  • Represented Allergan against Wilshire, Somerset, and Aurobindo on patents related to ophthalmic formulations of alcaftadine, for once-daily treatment of allergic conjunctivitis
  • Represented Alnylam against Silence Therapeutics on patents related to RNAi technology
  • Represented Allergan against Prinston Pharmaceutical on patents related to tablet formulations of nebivolol hydrochloride and valsartan to treat hypertension
  • Represented AstraZeneca against Andrx, Genpharm, Dr. Reddy, and Schwartz Pharma on patents related to omeprazole and its formulations
  • Represented Bristol-Myers Squibb against the Regents of the University of Michigan, Repligen Corp., and ZymoGenetics on patents related to synthetic fusion proteins for regulating the immune system
  • Represented UCB against Mylan, Dr. Reddy, Sandoz, and Cobalt on patents related to levetiracetam, a leading epilepsy medicine
  • Represented GlaxoSmithKline against Barr Pharmaceuticals on patents related to dutasteride, a leading BPH drug
  • Represented UCB and Celltech against KV Pharmaceutical on patents related to methylphenidate hydrochloride, an ADHD medicine

Representative Clients

  • Alkermes
  • Allergan
  • Alnylam
  • Bill & Melinda Gates Foundation and Gates MRI
  • Materia
  • Shionogi
  • Stemline
  • UCB




  • J.D. cum laude University of Notre Dame Law School 1999
  • B.S. Chemistry high distinction University of Illinois Urbana-Champaign 1996
  • B.S. Biochemistry University of Illinois Urbana-Champaign 1996

Bar Admissions

  • New York

Court Admissions

  • U.S. Supreme Court
  • U.S. District Court for the Eastern District of New York
  • U.S. District Court for the Southern District of New York
  • U.S. Court of Federal Claims

Professional Memberships and Activities

  • Board trustee, Foundation for Advancement of Diversity in IP Law (FADIPL)
  • Vice president, Executive Committee Member & Board Trustee, Foundation for Advancement of Diversity in IP Law (FADIPL)
  • Member, Venable Board
  • Member, Advisory Board, Center for Biosimilars


  • Managing Intellectual Property, IP Star, 2019 – 2020, 2022 – 2023
  • National Law Journal, Elite Boutique Trailblazer, 2017 (Inaugural list)
  • Client Choice Award, Intellectual Property, United States and New York, 2017 (Individual award)
  • IAM Patent 1000, The World’s Leading Patent Professionals, 2018, 2021 – 2023
  • LMG Life Sciences, Leading Lawyer, 2017 – 2020
  • Super Lawyers,
    • Intellectual Property Litigation, New York Metro, 2023
    • Rising Star, Intellectual Property Litigation, New York Metro, 2012 – 2015
  • Legal 500, Patent Litigation: Full Coverage, 2008 – 2009
  • Lawline, Furthered 40
  • Lawyers of Color, Law Firm Leaders, 2022



  • Volunteer mentor, College Admissions, UStrive Mentoring